NFKB1 and breast carcinoma: On the basis that curcumin inhibits NF-κB DNA binding, a phase II trial is currently recruiting breast cancer patients (ClinicalTrials.gov Identifier: NCT01740323) and a few other studies on curcumin are in the pipeline.